Full year results from Bioventix (BVXP) were issued this morning. I hold shares in them. They sell diagnostic antibodies including a troponin test which is a marker for past heart attacks.
I spent some time in my local A&E department a few weeks ago with chest pains which was confirmed as a possible heart attack via a troponin test but later turned out to be a mirage and I was quickly discharged. Don’t know whose troponin test they were using.
BVXP results were good, with EPS better than forecast and a second interim dividend being paid to make total dividends the same as last year. Revenue was up 9% and this is a “steady growth” share in essence. I am happy to continue holding as the yield of 4% is good even if the shares are not likely to excite in the short term.
Roger Lawson (Twitter https://twitter.com/RogerWLawson )
You can “follow” this blog by entering your email address in the box below. You will then receive an email alerting you to new posts as they are added.